FLT3 and acute myeloid leukemia: Quizartinib was FDA-approved in 2023 following a phase III QuANTUM trial (NCT02039726) that compared the use of quizartinib vs. salvage chemotherapy in AML patients with FLT3-ITD mutations only and respectively led to a longer median overall survival in the intent-to-treat population (6.2 vs. 4.7 months) and when censored for stem cell transplant (5.7 vs. 4.6 months) [52].